title: Clinical and microbiological effects of levofloxacin in the treatment of Aggregatibacter actinomycetemcomitans-associated periodontitis: a randomized placebo-controlled clinical trial.
abstract: OBJECTIVE
  To evaluate the clinical and microbiological effects of systemic levofloxacin (LFX) in subjects with Aggregatibacter actinomycetemcomitans-associated chronic periodontitis (AA-ACP).
  
  
  METHODS
  Subjects with severe periodontitis with subgingival detection of A. actinomycetemcomitans were randomly divided into two treatment groups; a test group (n = 35) that received scaling and root planing (SRP) and LFX (500 mg o.d.) and a control group (n = 34) that received SRP and placebo (o.d.) for 10 days. Plaque index (PI), gingival index (GI), percent of sites with bleeding on probing (% BoP), probing depth (PD) and clinical attachment level (CAL) were recorded and subgingival plaque samples were cultivated for detection of A. actinomycetemcomitans at baseline to 6 months at various intervals.
  
  
  RESULTS
  Subjects receiving LFX showed the greatest improvements in mean PD and CAL. The difference in the reduction of PD and CAL in the two groups was significant at 1, 3 and 6 months for PD and 3 and 6 months for CAL (p < 0.05). The inter-group difference in PI, GI and % BoP was not significant at any interval. Detectable levels of A. actinomycetemcomitans were significantly less in the test group 3 and 6 months post-therapy.
  
  
  CONCLUSIONS
  Systemic LFX as an adjunct to SRP improves clinical outcomes and suppresses A. actinomycetemcomitans below detectable levels.
authors: A R
authors: AR
authors: Pradeep
authors: Sonender Pal
authors: SP
authors: Singh
authors: Santosh S
authors: SS
authors: Martande
authors: Savitha B
authors: SB
authors: Naik
authors: Nitish
authors: N
authors: Kalra
authors: N
authors: N
authors: Priyanka
mesh_terms: D000328:Adult; D016976:Aggregatibacter actinomycetemcomitans / Q000187:drug effects* / Q000302:isolation & purification; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D058491:Bacterial Load / Q000187:drug effects; D055113:Chronic Periodontitis / Q000188:drug therapy / Q000382:microbiology*; D003131:Combined Modality Therapy; D003773:Dental Plaque / Q000382:microbiology; D003774:Dental Plaque Index; D012534:Dental Scaling / Q000379:methods; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D005884:Gingival Hemorrhage / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D064704:Levofloxacin / Q000627:therapeutic use*; D008297:Male; D016871:Pasteurellaceae Infections / Q000188:drug therapy*; D017622:Periodontal Attachment Loss / Q000188:drug therapy / Q000382:microbiology; D010512:Periodontal Index; D010514:Periodontal Pocket / Q000188:drug therapy / Q000382:microbiology; D010919:Placebos; D016745:Root Planing / Q000379:methods; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D010919:Placebos; D064704:Levofloxacin